Answers are grounded in this paper and cite their sources.
Experimental findings demonstrate that Ephx2 deficiency reduces ferroptosis in COPD, suggesting a new treatment avenue.
These results suggest that Ephx2 deficiency inhibits ferroptosis to alleviate CS-induced emphysema, primarily by mitigating its inhibitory effect on the cystine/glutathione/glutathione peroxidase 4 axis. Therefore, Ephx2 represents an effective therapeutic target in CS-induced chronic obstructive pulmonary disease (COPD).
No takes yet. Share an insight, caveat, or question.
He et al. (2026) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: